Alphabet Inc Class A (GOOGL) Stock Price Today
Aura AI Summary
Key Stats
- $3.95TMarket Cap
- 27,685,187Volume
- MediaSector
- $402.6252W High
- $253.0852W Low
- 87 DaysTypical Hold Time
- $3.83TEnterprise Value
- 0.27%Div Yield
- 69% Sell | 31% BuyTrading Activity
Track Alphabet Inc Class A (GOOGL) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Alphabet Inc Class A has traded between a low of $253.08 and a high of $402.62, highlighting its annual price range. Buy and sell Alphabet Inc Class A shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Most Recent News
CHMP recommends approval of Johnson & Johnson's TALVEY plus daratumumab for earlier treatment of relapsed/refractory multiple myeloma.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...

CHMP recommends approval of Johnson & Johnson's TALVEY® plus daratumumab for earlier treatment of relapsed multiple myeloma
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...

CHMP recommends approval of Johnson & Johnson's TALVEY® with daratumumab for earlier treatment of relapsed/refractory multiple myeloma.
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.